ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has launched the ICON Signature Series, a new thought leadership program that offers expert insight into value-driven strategies for clinical development.
Built on over 20 years of helping biopharma companies accelerate the development of their drugs, ICON Signature Series brings together ICON and industry experts to share knowledge and expertise across all aspects of clinical development and post-approval strategies. Knowledge will be shared using a broad range of communication channels, including webinars, articles, whitepapers, symposia, workshops and videos. The program also offers an interactive discussion forum for biopharma companies to engage with ICON experts and their industry peers on the latest industry trends and developments.
Commenting on the ICON Signature Series, Dr. Mark Roseman, Executive Vice President, Global Scientific Operations at ICON, said: "Our global team comprises a powerhouse of deep insight in all fields related to clinical R&D. This, coupled with their practical experience in local markets makes them uniquely qualified to offer expert guidance on development practices, comment on emerging issues, and help steer the industry's conversation on its future. The ICON Signature Series will be an invaluable resource to sponsor companies and is part of ICON’s on-going commitment to provide clients with strategic development solutions.”
The next ICON Signature Series webinar, entitled Enrichment Strategies for achieving greater clinical trial success takes place on 22nd April.
Expert Panelists include:
· Mr. Tim Clark, VP Scientific Affairs – ICON Clinical Research
· Professor Klaudius Siegfried – VP CNS – ICON Clinical Research
· Dr. Jamal Gasmi – VP Oncology, ICON Clinical Research
For more information on ICON Signature Series feature topics, visit http://www.iconplc.com/ICONSignatureSeries/